Date: 2026-04-24Category: Press ReleaseState: Union GovernmentCountry: India
IPC Signs MoUs with the Pharmaceuticals & Medical Devices Bureau of India and National Institute of Pharmaceuticals Education & Research, Hajipur, to Promote Drug Quality, Research, and Patient Safety
**Executive Summary**
On April 24, 2026, the Indian Pharmacopoeia Commission (IPC) signed two Memoranda of Understanding (MoUs) with the Pharmaceuticals & Medical Devices Bureau of India (PMBI) and the National Institute of Pharmaceutical Education and Research (NIPER), Hajipur. These agreements aim to enhance drug quality assurance, advance pharmaceutical research in biologics, and strengthen pharmacovigilance across the Jan Aushadhi Kendra network. Key actions include random drug testing, the establishment of new pharmacopoeial standards for emerging therapies, and specialized training for pharmacy professionals.
**Key Points / Main Content**
**IPC–PMBI Partnership (Quality and Pharmacovigilance)**
* **Quality Testing:** PMBI will submit randomly selected batches of Jan Aushadhi medicines to the IPC for rigorous quality testing to enhance the quality assurance framework.
* **Rational Drug Use:** The collaboration promotes the use of the National Formulary of India (NFI) across all Pradhan Mantri Bhartiya Janaushadhi Kendras (PMBJKs).
* **Adverse Drug Reaction (ADR) Reporting:** PMBJKs will display Pharmacovigilance Programme of India (PvPI) QR codes and a toll-free helpline (1800-180-3024) to encourage ADR reporting.
* **Professional Training:** The IPC and PMBI will conduct joint training and awareness programs for pharmacists regarding ADR reporting tools and the rational use of medicines.
**IPC–NIPER Hajipur Partnership (Research and Academic Exchange)**
* **Impurity Profiling:** Joint research will focus on identifying genotoxic impurities, such as nitrosamines, and correlating them with ADR data to set evidence-based limits.
* **Standard Development:** The institutions will develop analytical methods, quality control protocols, and reference standards for biologics, biosimilars, and cell and gene therapy products.
* **Resource Sharing:** The agreement includes sharing advanced analytical instrumentation facilities and initiating faculty exchange programs.
* **Educational Support:** The partnership establishes internship and fellowship opportunities for pharmacy graduates and postgraduates, alongside the joint publication of research and training manuals.
**Impact Analysis**
**Stakeholder: Pharmaceuticals & Medical Devices Bureau of India (PMBI) and PMBJKs**
**Impact**
The quality assurance framework for Jan Aushadhi medicines will be significantly strengthened through IPC's testing capabilities and standardized formulary usage.
**Action Required**
Submit random medicine batches for testing and ensure the mandatory display of PvPI QR codes and helpline numbers at all retail locations.
**Stakeholder: NIPER Hajipur and Pharmacy Students**
**Impact**
Faculty and students gain access to advanced instrumentation and collaborative research opportunities in high-growth areas like biologics and gene therapy.
**Action Required**
Engage in joint research programs, utilize shared facilities, and participate in newly established internship and fellowship tracks.
**Stakeholder: Pharmacists and Healthcare Stakeholders**
**Impact**
They will receive enhanced technical training and resources to improve patient safety and rational drug administration.
**Action Required**
Participate in sensitization and training programs organized by the IPC and PMBI.
**Stakeholder: General Public/Patients**
**Impact**
Patients benefit from increased transparency regarding drug safety and more accessible channels for reporting side effects.
**Action Required**
Utilize the provided toll-free helpline and QR codes at Jan Aushadhi Kendras to report suspected adverse drug reactions.
Key Entities Referenced
Indian Pharmacopoeia Commission (IPC): The primary signatory and autonomous body responsible for setting drug standards and quality testing of medicines.
Pharmaceuticals & Medical Devices Bureau of India (PMBI): The agency collaborating with IPC to enhance quality assurance and promote rational drug use within the generic medicine network.
National Institute of Pharmaceutical Education and Research (NIPER), Hajipur: An autonomous institute collaborating with IPC on pharmaceutical research, impurity profiling, and standards for biologics and cell therapies.
Pradhan Mantri Bhartiya Janaushadhi Kendras (PMBJKs): The nationwide network of generic medicine outlets where the quality assurance framework and pharmacovigilance activities will be implemented.
Pharmacovigilance Programme of India (PvPI): The initiative being strengthened across PMBJKs to monitor and report adverse drug reactions through QR codes and helplines.
Ministry of Health and Family Welfare
IPC Signs MoUs with the Pharmaceuticals &
Medical Devices Bureau of India and National
Institute of Pharmaceuticals Education &
Research, Hajipur, to Promote Drug Quality,
Research, and Patient Safety
IPC–PMBI Partnership to Transform Quality Assurance,
Strengthen Pharmacovigilance, and Institutionalize Rational
Drug Use Across Jan Aushadhi Kendras Nationwide
IPC–NIPER Hajipur MoU to Advance Pharmaceutical
Research, Strengthen Pharmacopoeial Standards, and
Enhance Safety of Biologics and Emerging Therapies
Posted On: 24 APR 2026 12:13PM by PIB Delhi
Under the visionary leadership of Hon’ble Prime Minister Shri Narendra Modi, India continues to
strengthen its commitment to ensuring access to quality healthcare and advancing pharmaceutical
excellence through strategic institutional collaborations. In line with this vision, the Indian Pharmacopoeia
Commission (IPC), Ministry of Health and Family Welfare, Government of India, signed two significant
Memoranda of Understanding (MoUs) with the Pharmaceuticals & Medical Devices Bureau of India
(PMBI), Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Government of India, and
the National Institute of Pharmaceutical Education and Research (NIPER), Hajipur, Bihar, an autonomous
institution under the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Government
of India.The MoU between IPC and PMBI aims to enhance the quality assurance framework for medicines made
available through Pradhan Mantri Bhartiya Janaushadhi Kendras (PMBJKs). Under this collaboration,
PMBI may submit randomly selected batches of Jan Aushadhi medicines to IPC for quality testing. The
partnership will further promote the use of the National Formulary of India (NFI) across Pradhan Mantri
Bhartiya Janaushadhi Kendras (PMBJKs) to ensure rational use of medicines. It also seeks to strengthen
pharmacovigilance activities by displaying the Pharmacovigilance Programme of India (PvPI) QR code
and toll-free helpline number (1800-180-3024) at PMBJKs across the country, thereby encouraging
adverse drug reaction (ADR) reporting and improving patient safety. In addition, IPC and PMBI will
jointly organize sensitization, awareness, and training programmes for pharmacists and stakeholders on
rational use of medicines, pharmacovigilance, ADR reporting tools, and the role of pharmacists in
safeguarding public health.
The MoU signed between IPC and NIPER, Hajipur focuses on collaborative research, academic exchange,
and capacity building in the area of pharmaceutical science and healthcare products. NIPER Hajipur, an
Institute of National Importance, possesses advanced expertise in pharmaceutical analysis, biologics, and
clinical research, making it a valuable partner in strengthening pharmacopoeial science and patient safety.
This collaboration will include joint research programmes on impurity profiling, including genotoxic
impurities such as nitrosamines, and their correlation with adverse drug reaction data to establish
evidence-based pharmacopoeial limits. It will also focus on the development of analytical methods,
quality control protocols, and reference standards for biologics, biosimilars, and emerging cell and gene
therapy products for inclusion in the Indian Pharmacopoeia.
Both institutions will also collaborate in organizing training programmes, workshops, seminars, and
conferences, along with faculty exchange initiatives and sharing of advanced analytical instrumentation
facilities. Internship and fellowship opportunities for pharmacy graduates and postgraduates, as well as
joint publication of research papers, training manuals, and educational materials, will further strengthen
scientific engagement and institutional capacity building.
These MoUs reflect IPC’s continued efforts to strengthen India’s healthcare ecosystem by promoting
quality assurance, patient safety, rational use of medicines, and innovation in pharmaceutical standards.
Such collaborations will further reinforce India’s position as a global leader in pharmaceutical quality,
regulatory excellence, and public health advancement.
*****
SR
HFW/IPC Signs MoUs with PMBI & NIPER to Improve Drug Quality, Research & Patient
Safety/24 April 2026/1(Release ID: 2255190) Visitor Counter : 676
Read this release in: Urdu , ही , Punjabi